V Wealth Advisors’s Inovio Pharmaceuticals INO Stock Holding History

V Wealth Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1	Closed	–	–	446
2017 Q2	$0	Buy	+1	New	+$86	﹤0.01%	817

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

V Wealth Advisors's INO Position: Q3 2017 in Review

V Wealth Advisors sold out of Inovio Pharmaceuticals (INO) in Q3 2017, closing a stake of 1 share.

V Wealth Advisors first reported a position in INO in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 125 funds tracked by Wall St. Rank hold INO as of Q3 2017.

V Wealth Advisors reported no remaining Inovio Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 1 Inovio Pharmaceuticals share in Q3 2017.
V Wealth Advisors first reported a position in Inovio Pharmaceuticals in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Inovio Pharmaceuticals position peaked at $0 in Q2 2017.
125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.